Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
Cancer Management and Research · 2024-07 · Volume 16 · 933-939
DOI: 10.2147/cmar.s325514 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Management and Research, 2024-07. Verfasst von Michelle M Dugan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
- Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
ORCID-Profile: Michelle M Dugan, Jonathan S Zager
Zitieren
APA
Dugan, M. M., Perez, M. C., Karapetyan, L., & Zager, J. S. (2024). Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives. Cancer Management and Research, Volume 16, 933-939. https://doi.org/10.2147/cmar.s325514
Vancouver
Dugan MM, Perez MC, Karapetyan L, Zager JS. Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives. Cancer Management and Research. 2024;Volume 16:933-939. doi:10.2147/cmar.s325514
BibTeX
@article{Dugan2024,
author = {Dugan, Michelle M and Perez, Matthew C and Karapetyan, Lilit and Zager, Jonathan S},
title = {Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives},
journal = {Cancer Management and Research},
year = {2024},
volume = {Volume 16},
pages = {933--939},
doi = {10.2147/cmar.s325514}
}
EUVIMED